Payment overview · 2025
General Payments
$933.74
40 reported records · 15 companies
Healthcare provider profile · identity verified
Cody Fields, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Surgical · KNOXVILLE, TN · NPI 1437634680
Verified facts
What the public records show
CMS Open Payments records show Cody Fields, PA-C received $933.74 in general payments during 2025 across 40 reported records.
AtriCure, Inc. accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $256.85 | 27.5% | 16 | 2025 |
| Mayne Pharma Commercial LLC | Unresolved — no canonical attribution shown | $125.00 | 13.4% | 1 | 2025 |
| SMOKY MOUNTAIN SURGICAL LLC | Unresolved — no canonical attribution shown | $106.05 | 11.4% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $70.03 | 7.5% | 3 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $65.71 | 7.0% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $49.24 | 5.3% | 3 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $41.31 | 4.4% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $37.47 | 4.0% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $36.69 | 3.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.05 | 3.8% | 1 | 2025 |
| Haemonetics Corporation | Unresolved — no canonical attribution shown | $24.13 | 2.6% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $23.65 | 2.5% | 1 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $23.57 | 2.5% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $22.78 | 2.4% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $16.21 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $933.74 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $176.70 | 11 | 2025 |
Source payment records
|
|||||
| ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Normalized: atricure cryoice cryosphere cryoablation system |
Device | AtriCure, Inc. | $139.17 | 9 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $130.66 | 8 | 2025 |
Source payment records
|
|||||
| BIJUVA Normalized: bijuva |
Drug | Mayne Pharma Commercial LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| EPIC Normalized: epic |
Device | Abbott Laboratories | $70.03 | 3 | 2025 |
Source payment records
|
|||||
| Echelon; Endopath Normalized: echelon endopath |
Device | Ethicon US, LLC | $65.71 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $49.24 | 3 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $41.31 | 2 | 2025 |
Source payment records
|
|||||
| MITRIS RESILIA Mitral Valve Normalized: mitris resilia mitral valve |
Device | Edwards Lifesciences Corporation | $37.47 | 1 | 2025 |
Source payment records
|
|||||
| PREVELEAK Normalized: preveleak |
Device | Baxter Healthcare | $36.69 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $35.05 | 1 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $34.79 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $34.79 | 1 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| TEG5000 HEMOSTASIS ANALYZER Normalized: teg5000 hemostasis analyzer |
Device | Haemonetics Corporation | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| RESTOREFLOW Normalized: restoreflow |
Device | LeMaitre Vascular, Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| ARISTA Normalized: arista |
Device | Davol Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| STERNALOCK Normalized: sternalock |
Device | Zimmer Biomet Holdings, Inc. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| AtriCure cryoICE Cryoablation System (CRYO2) Normalized: atricure cryoice cryoablation system cryo2 |
Device | AtriCure, Inc. | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| FIBRYGA Normalized: fibryga |
Biological | Octapharma USA, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 26 | 26 |
| Potassium Chloride | Potassium Chloride | 21 | 20 |
| Furosemide | Furosemide | 19 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | 19 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $933.74 · 40 records | AtriCure, Inc. | ARISTA, ATRICLIP LAA EXCLUSION SYSTEM, ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM, AURORA EV-ICD MRI SURESCAN, AtriCure cryoICE Cryoablation System (CRYO2), BIJUVA, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, EPIC, Echelon; Endopath, FIBRYGA, LifeVest, MITRIS RESILIA Mitral Valve, PREVELEAK, RESTOREFLOW, Restrata Wound Matrix, STERNALOCK, SURGIFLO Hemostatic Matrix, SYNERGY ABLATION SYSTEM, TEG5000 HEMOSTASIS ANALYZER, VISTASEAL | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error